BioSpace News Archive

Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (“Therma” or the “Company”), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, announced that on May 31, 2023,

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the “Company” or “TELO”) announces that it has entered into an agreement with Leede Jones Gable Inc.

Genentech, a member of the Roche Group, announced new long-term data for Evrysdi® from the open-label extension of the pivotal FIREFISH study, reinforcing its sustained efficacy and safety profile in children with Type 1 spinal muscular atrophy.

Horizon Therapeutics plc announced the presentation of a new analysis of MRI data from the Phase 3 clinical trial of UPLIZNA showing a reduction in the formation of subclinical transverse myelitis lesions in people with NMOSD.

Cerecin Inc. presented encouraging findings from a recent study on CER-0001, an investigational ketogenic agent, indicating that certain individuals suffering from migraines may experience benefit.

Zealand Pharma A/S announced the submission of a New Drug Application to the US Food and Drug Administration for dasiglucagon for the prevention and treatment of low blood sugar in pediatric patients 7 days of age or older with congenital hyperinsulinism.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

MDxHealth SA, a commercial-stage precision diagnostics company, held an extraordinary general shareholders’ meeting.

PDS Biotechnology Corporation announced, on June 28, 2023, PDS Biotech granted nonstatutory stock options to purchase a total of 29,900 shares of common stock to four employees as a material inducement to employment with PDS Biotech and in accordance with Nasdaq Listing Rule 5635 and PDS Biotech’s 2019 Inducement Plan, as amended, which was adopted on June 17, 2019 and provides for the granting of equity awards to new employees of PDS Biotech.

X4 Pharmaceuticals announced that, effective on June 29, 2023, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.